Ribociclib FDA label updated to include pre- and perimenopausal women©United States Food and Drug Agency

FDA approved avatrombopag for thrombocytopenia in CLD patients scheduled for a procedure

/1 Comment/in /by

 

You might also like
us-fda-approval-medipaper-medical-communications-agency-medical-writer-agency-apac-asia-pacific-HK-hong-kong-oncology-CV-neurology-immunotherapy-obesity-diabetes-specialty-infectious.jpg Pembrolizumab approved for advanced gastric cancer
Ribociclib FDA label updated to include pre- and perimenopausal women©United States Food and Drug Agency Frontline nivolumab plus ipilimumab approved for intermediate or poor risk advanced RCC
FDA approved abiraterone acetate tablets plus prednisone for metastatic high-risk CSPC
Ribociclib FDA label updated to include pre- and perimenopausal women©United States Food and Drug Agency Bevacizumab in combination with carboplatin and paclitaxel FDA approved for several types of gynaecological cancers
Ribociclib FDA label updated to include pre- and perimenopausal women©United States Food and Drug Agency Ipilimumab plus nivolumab FDA approved for MSI-H and dMMR pre-treated mCRC
Glasdegib plus low-dose cytarabine (LDAC) approved in elderly AML patients
Trastuzumab-biosimilar Herzuma® FDA approved in HER2+ breast cancer
MediPr medipr.org medi-paper.com MediNews Asia MediNews.asia MediNews.cn MediPaper Medical Communications Ltd Healthcare Writers Medical Writers Medical Writer Agency Hong Kong Medical Writing Services Solutions Quote 醫學寫作 香港 醫學作家香港©United States Food and Drug Agency US FDA Duvelisib FDA approved for adult patients with R/R CLL or SLL
1 reply

Trackbacks & Pingbacks

  1. FDA approved avatrombopag for thrombocytopenia in CLD patient scheduled for a procedure - MediNews Asia says:
    23rd May 2018 at 11:47 PM

    […] post FDA approved avatrombopag for thrombocytopenia in CLD patient scheduled for a procedure appeared first on Medical Writer Agency | 香港醫學作家 | MediPR | MediPaper Hong […]

Leave a Reply

Want to join the discussion?
Feel free to contribute!

Leave a Reply